Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company focuses on non-genetically engineered T cell therapies, specifically its MultiTAA product candidates, which target multiple tumor antigens without requiring genetic modifications. This approach aims to enhance safety and efficacy by avoiding lymphodepletion or preconditioning, making the treatment more accessible and less invasive for patients.

Marker Therapeutics has demonstrated significant achievements in clinical studies, where its MultiTAA therapies have shown to be safe and effective, inducing durable anti-tumor responses and epitope spreading to the patient's immune system. These advancements highlight the potential of Marker Therapeutics' innovative approach in the immuno-oncology field, positioning the company as a leader in non-genetically engineered T cell therapies.